An Analysis of the SALT 1 and SALT 2 Studies
Frederick Alan Rapoport, MD, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia
Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia.
Clinical Pearls:
- The SALT 1 and SALT 2 studies, which looked at the efficacy of tolvaptan (Samsca), found that there was a statically significant improvement in patients’ serum sodium levels compared to placebo after 30 days
- Most improvement occurred within the first 4 days
- Patients should be monitored in a hospital for the first four days and remain closely monitored after that to ensure that there is not an overcorrection of the serum sodium levels.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
